US+1 646-781-8004
Europe+44-203-868-8738
APAC+91-744-778-0008
sales@meticulousresearch.com
Resources 
    • About Us 

    • Home Report Store Cancer/Tumor Profiling Market
    Cancer/Tumor Profiling Market

    Cancer/Tumor Profiling Market Size, Share, Forecast, & Trends Analysis by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH) Cancer Type (Breast, Prostate) Application (Clinical, Research) End User (Pharma, Academic) - Global Forecast to 2031

    Report ID:MRHC - 104947 Pages: 270 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 Hours

    Cancer/Tumor Profiling Market Size & Forecast

    The Cancer/Tumor Profiling Market is projected to reach $24.70 billion by 2031 at a CAGR of 10.9% from 2024 to 2031. The rise in cancer cases, the growing research of novel molecules, and the increasing number of genomic research projects have increased the demand for cancer/tumor profiling. The emergence of tumor profiling has removed the restraints of traditional cancer/tumor classification approaches, which rely on the morphology of the cancerous cells and the surrounding tissues. Today, cancer/tumor profiling is accepted as the standard technique for classifying tumors, with the guidelines associated with the European Society for Molecular Oncology (ESMO) and the College of American Pathologists (CAP).

    The profiling of tumors with advanced technologies such as ISH, NGS, IHC, and PCR has successfully analyzed the genes, amplicons, and gene regions with familiar involvement with tumors. This approach, also known as targeted treatment, delivers high sensitivity for detecting tumor subclones or rare mutations, providing increased visibility regarding important mutations acting as drivers of cancer.

    The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS setups and long turnaround times restrain the growth of this market.

    Additionally, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities. However, the lack of genetic experts for interpreting results, the non-availability of in-house tumor profiling technologies, and the high number of false biomarker discoveries are major challenges for the stakeholders in the cancer/tumor profiling market.

    Cancer/Tumor Profiling Market Growth Drivers

    Advancements in Multi-omics Tumor Profiling and Cancer Research

    Cancer research has benefited from the advancement in omics technologies from genomics to transcriptomics and from a wide variety of resources obtained from multiple omics datasets originating from the patients. Multi-omics approaches offer a unique opportunity to identify cancer patients' clinical and molecular features. In transcriptomics and genomics, there is an unmet need to distinguish between inconsistency in related biological procedures, like differences in variability or post-translational changes in the expression profiles due to the role of mRNA transcripts in the development of cancer.

    Recent advancements in proteomics have facilitated the emergence of proteogenomic approaches. These approaches seamlessly integrate genomic data with proteomics data, including insights into post-translational modifications such as acetylation and protein phosphorylation. These developments in multi-omics tumor profiling and cancer research are expected to drive the growth of the cancer/tumor profiling market.

    Cancer/Tumor Profiling Market

    Click here to: Get Free Sample Pages of this Report

    Increasing Prevalence of Cancer

    The burden of cancer is growing globally. According to GLOBOCAN 2020, cancer incidence is expected to increase from 19.3 million in 2020 to 30.2 million in 2040. Moreover, the mortality due to cancer is estimated to increase from 9.9 million in 2020 to 16.3 million in 2040. Nearly 70% of the total deaths due to cancer occur in low and middle-income countries. Early detection is extremely important in reducing mortality, improving patients’ chances of survival, and saving on treatment costs. Various methods are used to detect cancer. The demand for cancer/tumor profiling for cancer diagnosis is expected to grow significantly in the coming years.

    Advancements in Multi-omics Tumor Profiling

    During the last decade, genomics and proteomics approaches have become effective and crucial tools in the clinical research of biological pathways involved in cancer pathogen replication, host response, and disease progression. Genomics and proteomics are important for discovering and understanding host-pathogen interactions. They offer the opportunity to improve personalized treatments and disease prevention in advanced cancer cases. Genomics primarily aims to sequence, assemble, and analyze the functions and structures of genomes. At the same time, proteomics helps in the large–scale study of the complete set of proteins within an organism. Such developments in genomics and proteomics are expected to drive the cancer/tumor profiling market.

    Cancer/Tumor Profiling Market Opportunity

    Increasing Focus on the Development of Personalized Medicines Creating Market Growth Opportunities

    Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. The synthesis of genes can rapidly sequence large sections of a person’s genome and aid in the formulation of precision medicine, in turn generating cost-effective alternatives to existing therapies and allowing for novel treatments. Personalized medicine analyzes molecules, individual genes, and networks and translates them into an overall output for the systems of the human body. These medicines can tailor therapies with the best responses and highest safety margins, ensuring better patient care. Moreover, precision medicines help cure diseases and enhance the chances of saving people undergoing treatments for life-threatening diseases. Furthermore, cancer treatment and diagnosis are also advancing significantly with the increased adoption of advanced technologies such as PCR, NGS, FISH, and ISH in precision medicine.

    New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. This rapidly developing field has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with next–generation sequencing (NGS) technology. Furthermore, personalized medicine contributes to advancements in new therapies for cancer treatment, the development of new methods for disease detection, and the development of preventive medicines. Thus, the increasing inclination toward personalized medicine-based diagnosis and treatment is expected to create opportunities for market growth.

    Cancer/Tumor Profiling Market Analysis: Key Findings

    Based on Biomarker Type, the Genetic Biomarkers Segment is Expected to Account for the Largest Share of the Market in 2024

    Based on biomarker type, the cancer/tumor profiling market is segmented into genetic biomarkers and protein biomarkers. In 2024, The genetic biomarkers segment is expected to account for the largest share of 72.0% of the cancer/tumor profiling market. The large market share of this segment is attributed to the benefits offered by genetic biomarkers, including their reliability in identifying drug-resistant cancer cells, assisting in identifying genetic patterns responsible for future cancer recurrence, and their increased use for the early detection of cancer.

    Based on Technology, the Next-Generation Sequencing (NGS) Segment is Expected to Account for the Largest Share of the Market in 2024

    Based on technology, the cancer/tumor profiling market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. In 2024, the next-generation sequencing (NGS) segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the benefits offered by NGS, such as high-throughput production, efficient instrument runs, and cost-effectiveness compared to traditional first-generation sequencing methods. Additionally, NGS is highly preferred for large-scale genomic profiling and transcriptomic sequencing.

    Based on Cancer Type, the Breast Cancer Segment is Expected to Account for the Largest Share of the Market in 2024

    Based on Cancer Type, the cancer/tumor profiling market is segmented into breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, and other cancer types. In 2024, The breast cancer segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the rising incidence of breast cancer cases and the increasing adoption of tumor profiling for breast cancer.

    Based on Application, the Research Applications Segment is Expected to Account for the Largest Share of the Market in 2024

    Based on application, the cancer/tumor profiling market is segmented into clinical applications and research applications. In 2024, the research applications segment is expected to account for the largest share of the cancer/tumor profiling market. The large market share of this segment is attributed to the decreasing cost of sequencing procedures, the rising research and development efforts by pharmaceutical and biopharmaceutical companies in drug and biomarker discovery, the high sensitivity and throughput offered by advanced profiling technology, and the expanding applications of cancer/tumor profiling in various clinical and research areas.

    Based on End User, the Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market in 2024

    Based on End User, the cancer/tumor profiling market is segmented into pharmaceutical & biopharmaceutical companies, hospitals & diagnostic laboratories, academic & research institutes, and contract research organizations (CROs). In 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of 40.9% of the cancer/tumor profiling market. The large market share of this segment is attributed to the declining costs of sequencing, the increase in research and development activities by pharmaceutical and biopharmaceutical companies, and the extensive utilization of advanced profiling solutions for cancer studies.

    Geographical Analysis

    In 2024, North America is expected to account for the largest share of 42.7% of the cancer/tumor profiling market. North America’s significant market share can be attributed to the high prevalence of cancer, substantial healthcare expenditure, widespread adoption of advanced molecular technologies, and substantial investment in pharmaceutical R&D.

    Cancer/Tumor Profiling Market: Key Companies

    The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2021–2024). The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

    Cancer/Tumor Profiling Industry Overview: Latest Developments from Key Industry Players

    • In May 2023, Thermo Fisher Scientific Inc. (U.S.) launched the Orbitrap Astral mass spectrometer, which combines high sensitivity, fast throughput, and deep proteome coverage, allowing researchers to identify new clinical biomarkers and develop new interventions from cardiovascular disease to cancer.
    • In March 2023, Thermo Fisher Scientific Inc. (U.S.) collaborated with Arsenal Biosciences, Inc. (U.S.), a clinical-stage cell therapy company operating in solid tumor therapies for developing advanced manufacturing processes for new cancer treatments.
    • In March 2023, Illumina, Inc. (U.S.) partnered with Myriad Genetics, Inc. (U.S.) to expand the partnership for broadening the accessibility and availability of oncology homologous recombination deficiency (HRD) testing in the U.S. This partnership also opened new doors for companion diagnostic (CDx) alliance for the pharmaceutical industry, enabling clinical research in gene-based and targeted therapies.
    • In September 2022, Illumina, Inc. (U.S.) launched its NovaSeq 6000 Dx, the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, along with Illumina Complete Long-Reads, XLEAP-SBS Chemistry, NextSeq 1000/2000 Roadmap, and NovaSeq X Series (NovaSeq X and NovaSeq X Plus).

    Cancer/Tumor Profiling Market Research Summary

    Particulars

    Details

    Number of Pages

    270

    Format

    PDF

    Forecast Period

    2024-2031

    Base Year

    2023

    CAGR

    10.9%

    Estimated Market Size (Value)

    $24.70 billion by 2031

    Segments Covered

    By Biomarker Type

    • Protein Biomarkers
    • Genetic Biomarkers

    By Technology

    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • In-situ hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Other Technologies
      (Note: Other technologies include immunoassays, microarrays, mass spectrometers, Sanger sequencing, pyrosequencing, and fragment analysis)

    By Application

    • Clinical Applications
    • Research Applications

    By Cancer Type

    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Lymphoma
    • Leukemia
    • Cervical Cancer
    • Other Cancer Types
      (Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and head & neck cancers)

    By End User

    • Pharmaceutical & Biopharmaceutical Companies
    • Hospitals & Diagnostic Laboratories
    • Academic & Research Institutes
    • Contract Research Organizations (CROs)

    Countries Covered

    North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America and Middle East & Africa

    Key Companies

    The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

    Key questions answered in the cancer/tumor profiling market report:

    The global cancer/tumor profiling market report covers the qualitative analysis and market sizing of biomarker type, cancer type, technology, application, and end user. This report involves the analysis of various segments of cancer/tumor profiling at the regional and country level. The report also provides insights on factors impacting market growth, factor analysis, case studies, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

    The cancer/tumor profiling market is projected to reach $24.70 billion by 2031, at a CAGR of 10.9% during the forecast period.

    Among the biomarkers covered in this report, the genetic biomarkers segment is expected to account for the largest share of the market in 2024.

    Among the technologies covered in this report, the next-generation sequencing (NGS) segment is expected to account for the largest share of the market in 2024. The large market share of this segment is attributed to the higher sensitivity of this technique compared to call variants, low sequencing costs compared to other sequencing technologies, and the availability of low-cost sequencers.

    Among the cancer types covered in the report, the breast cancer segment is expected to account for the largest share of the market in 2024. The increase in breast cancer cases, government initiatives promoting breast cancer treatment, increasing healthcare expenditure, and reimbursement for certain profiling technologies such as NGS drive the demand for cancer/tumor profiling for breast cancer.

    Among the applications covered in this report, the research applications segment is expected to hold the largest share of the market in 2024. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced profiling technologies like NGS and PCR within research protocols.

    Among the end users covered in this report, the pharmaceutical & biopharmaceutical companies segment is expected to hold the largest share of the market in 2024. The large market share of this segment is attributed to rising research efforts in biomarker discovery, the growing demand for precision medicine, and the increasing number of cancer studies aimed at advancing cancer treatment.

    The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling.

    Furthermore, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities.

    The key players profiled in the cancer/tumor profiling market study are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

    Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising investments in the healthcare sector and increasing genomic projects in these countries.

    Enquire
    Check Discount
    COVID-19

    This report provides pre & post COVID-19 market estimates.

    Download sample here
    Related Tag: Cancer/Tumor Profiling Market Molecular Profiling Cancer Molecular Profiling Comprehensive Genomic Profiling Cancer Gene Profiling Cancer Biomarkers Testing Solid Tumor Profiling
    Medical Technologies
    Healthcare

    1.    Introduction 
           1.1.    Market Definition and Scope 
           1.2.    Market Ecosystem 
           1.3.    Currency and Limitation 
           1.4.    Key Stakeholders 
    2.    Research Methodology 
           2.1.    Research Approach 
           2.2.    Process of Data Collection and Validation 
                     2.2.1.    Secondary Research 
                     2.2.2.    Primary Research/Interviews with Key Opinion Leaders of the Industry 
           2.3.    Market Sizing and Forecast 
                     2.3.1.    Market Size Estimation Approach 
                     2.3.2.    Growth Forecast Approach 
                     2.3.3.    Market Share Analysis 
           2.4.    Assumptions for the Study 
    3.    Executive Summary 
    4.    Market Insights 
           4.1.    Overview 
           4.2.    Market Insights 
                     4.2.1.    Impact Analysis of Market Dynamics 
                     4.2.2.    Factor Analysis 
           4.3.    Regulatory Analysis 
                     4.3.1.    North America 
                                  4.3.1.1.    U.S.
                                  4.3.1.1.    Japan
                                  4.3.1.1.    India
                                  4.3.1.2.    Canada 
                     4.3.2.    Europe 
                     4.3.3.    Asia-Pacific 
                                  4.3.3.1.    China 
                                  4.3.3.2.    Japan
                                  4.3.3.3.    India
                     4.3.4.    Latin America 
                     4.3.5.    Middle East 
           4.4.    Porter's Five Forces Analysis 
                     4.4.1.    Bargaining Power of Buyers 
                     4.4.2.    Bargaining Power of Suppliers 
                     4.4.3.    Threat of Substitutes 
                     4.4.4.    Threat of New Entrants 
                     4.4.5.    Degree of Competition 
    5.    Cancer/Tumor Profiling Market Assessment—by Biomarker Type 
           5.1.    Overview 
           5.2.    Genetic Biomarkers 
           5.3.    Protein Biomarkers 
    6.    Cancer/Tumor Profiling Market Assessment—by Cancer Type 
           6.1.    Overview 
           6.2.    Breast Cancer 
           6.3.    Colorectal Cancer 
           6.4.    Lung Cancer 
           6.5.    Prostate Cancer 
           6.6.    Lymphoma 
           6.7.    Leukemia 
           6.8.    Cervical Cancer 
           6.9.    Other Cancer Types 
    7.    Cancer/Tumor Profiling Market Assessment—by Technology 
           7.1.    Overview 
           7.2.    Next-Generation Sequencing (NGS) 
           7.3.    Polymerase Chain Reaction (PCR) 
           7.4.    In Situ Hybridization (ISH) 
           7.5.    Immunohistochemistry (IHC) 
           7.6.    Other Technologies 
    8.    Cancer/Tumor Profiling Market Assessment—by Application 
           8.1.    Overview 
           8.2.    Research Applications 
           8.3.    Clinical Applications 
    9.    Cancer/Tumor Profiling Market Assessment—by End User 
           9.1.    Overview 
           9.2.    Pharmaceutical & Biopharmaceutical Companies 
           9.3.    Hospitals & Diagnostic Laboratories 
           9.4.    Academic & Research Institutes 
           9.5.    Contract Research Organizations (CROs) 
    10.    Cancer/Tumor Profiling Market Assessment—by Geography 
             10.1.    Overview 
             10.2.    North America 
                         10.2.1.    U.S. 
                         10.2.2.    Canada 
             10.3.    Europe 
                         10.3.1.    Germany 
                         10.3.2.    France 
                         10.3.3.    U.K. 
                         10.3.4.    Italy 
                         10.3.5.    Spain 
                         10.3.6.    Rest of Europe 
             10.4.    Asia-Pacific 
                         10.4.1.    China 
                         10.4.2.    Japan 
                         10.4.3.    India 
                         10.4.4.    Rest of Asia-Pacific 
             10.5.    Latin America 
             10.6.    Middle East & Africa 
    11.    Competition Analysis 
             11.1.    Overview 
             11.2.    Key Growth Strategies 
             11.3.    Competitive Benchmarking 
             11.4.    Market Share Analysis (2023) 
                         11.4.1.    Thermo Fisher Scientific Inc. (U.S.) 
                         11.4.2.    Illumina, Inc. (U.S.) 
                         11.4.3.    F. Hoffmann-La Roche Ltd (Switzerland) 
                         11.4.4.    Exact Sciences Corporation (U.S.) 
                         11.4.5.    Qiagen N.V. (Netherlands) 
             11.5.    Competitive Dashboard 
                         11.5.1.    Industry Leaders 
                         11.5.2.    Market Differentiators 
                         11.5.3.    Vanguards 
                         11.5.4.    Emerging Companies 
    12.    Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
             12.1.    Thermo Fisher Scientific, Inc. 
             12.2.    Illumina, Inc. 
             12.3.    Qiagen N.V. 
             12.4.    F. Hoffmann-La Roche Ltd 
             12.5.    Exact Sciences Corporation 
             12.6.    Agilent Technologies, Inc. 
             12.7.    NanoString Technologies, Inc. 
             12.8.    HTG Molecular Diagnostics, Inc. 
             12.9.    Agendia Inc. 
             12.10.     Personalis, Inc. 
             12.11.    Tempus Labs, Inc. 
                           (Note: SWOT analyses of the top 5 companies will be provided.)
    13.    Appendix 
             13.1.    Available Customization 
             13.2.    Related Reports 

    List of Tables
    Table 1    Major Targeted Therapies and Corresponding Biomarkers 
    Table 2    Number of New Cancer Cases, by Type, 2020 Vs. 2030 
    Table 3    Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region 
    Table 4    Global Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 5    Germline Mutations in Hereditary Cancer Syndromes: Cancer-Causing Genes as Biomarkers of Risk 
    Table 6    Global Cancer/Tumor Profiling Market for Genetic Biomarkers, by Country/Region, 2022–2031 (USD Million) 
    Table 7    Global Cancer/Tumor Profiling Market for Protein Biomarkers, by Country/Region, 2022–2031 (USD Million) 
    Table 8    Global Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 9    Number of New Breast Cancer Cases Globally (2020–2035) 
    Table 10    Global Cancer/Tumor Profiling Market for Breast Cancer, by Country/Region, 2022–2031 (USD Million) 
    Table 11    Global Cancer/Tumor Profiling Market for Colorectal Cancer, by Country/Region, 2022–2031 (USD Million) 
    Table 12    Global Cancer/Tumor Profiling Market for Lung Cancer, by Country/Region, 2022–2031 (USD Million) 
    Table 13    Number of New Prostate Cancer Cases (2020–2035) 
    Table 14    Global Cancer/Tumor Profiling Market for Prostate Cancer, by Country/Region, 2022–2031 (USD Million) 
    Table 15    Number of New Non-Hodgkin Lymphoma Cancer Cases (2020–2035) 
    Table 16    Global Cancer/Tumor Profiling Market for Lymphoma, by Country/Region, 2022–2031 (USD Million) 
    Table 17    Estimated Number of New Leukemia Cases (2020–2035) 
    Table 18    Global Cancer/Tumor Profiling Market for Leukemia, by Country/Region, 2022–2031 (USD Million) 
    Table 19    Global Cancer/Tumor Profiling Market for Cervical Cancer, by Country/Region, 2022–2031 (USD Million) 
    Table 20    Number of New Cancer Cases (2020-2035) 
    Table 21    Global Cancer/Tumor Profiling Market for Other Cancer Types, by Country/Region, 2022–2031 (USD Million) 
    Table 22    Global Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 23    Global Next–Generation Sequencing (NGS) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 24    Global Polymerase Chain Reaction (PCR) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 25    Global In Situ Hybridization Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 26    Applications of IHC in Oncology and Related Antibodies 
    Table 27    Global Immunohistochemistry (IHC) Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 28    Global Other Technologies Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 29    Global Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 30    Currently Available Targeted Therapies and Corresponding Biomarkers 
    Table 31    Global Cancer/Tumor Profiling Market for Research Applications, by Country/Region, 2022–2031 (USD Million) 
    Table 32    Frequently Used Clinical Tumor Markers 
    Table 33    Global Cancer/Tumor Profiling Market for Clinical Applications, by Country/Region, 2022–2031 (USD Million) 
    Table 34    Global Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 35    Global Cancer/Tumor Profiling Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2022–2031 (USD Million) 
    Table 36    Global Cancer/Tumor Profiling Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million) 
    Table 37    Global Cancer/Tumor Profiling Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million) 
    Table 38    Global Cancer/Tumor Profiling Market for CROs, by Country/Region, 2022–2031 (USD Million) 
    Table 39    Global Cancer/Tumor Profiling Market, by Region, 2022–2031 (USD Million) 
    Table 40    Estimated Cancer Cases in North America: 2020–2030 
    Table 41    North America: Cancer/Tumor Profiling Market, by Country, 2022–2031 (USD Million) 
    Table 42    North America: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 43    North America: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 44    North America: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 45    North America: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 46    North America: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 47    U.S.: Key Macro & Micro Indicators 
    Table 48    U.S.: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 49    U.S.: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 50    U.S.: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 51    U.S.: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 52    U.S.: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 53    Canada: Key Macro & Micro Indicators 
    Table 54    Canada: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 55    Canada: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 56    Canada: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 57    Canada: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 58    Canada: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 59    Europe: Cancer/Tumor Profiling Market, by Country, 2022–2031 (USD Million) 
    Table 60    Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 61    Europe: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 62    Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 63    Europe: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 64    Europe: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 65    Germany: Key Macro & Micro Indicators 
    Table 66    Germany: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 67    Germany: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 68    Germany: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 69    Germany: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 70    Germany: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 71    France: Key Macro & Indicators 
    Table 72    France: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 73    France: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 74    France: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 75    France: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 76    France: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 77    U.K.: Key Macro & Micro Indicators 
    Table 78    U.K.: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 79    U.K.: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 80    U.K.: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 81    U.K.: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 82    U.K.: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 83    Italy: Key Macro & Micro Indicators 
    Table 84    Italy: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 85    Italy: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 86    Italy: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 87    Italy: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 88    Italy: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 89    Spain: Key Macro & Micro Indicators 
    Table 90    Spain: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 91    Spain: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 92    Spain: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 93    Spain: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 94    Spain: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 95    Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030 
    Table 96    Rest of Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 97    Rest of Europe: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 98    Rest of Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 99    Rest of Europe: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 100    Rest of Europe: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 101    Asia-Pacific: Cancer/Tumor Profiling Market, by Country/Region, 2022–2031 (USD Million) 
    Table 102    Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 103    Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 104    Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 105    Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 106    Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 107    China: Key Macro & Micro Indicators 
    Table 108    China: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 109    China: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 110    China: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 111    China: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 112    China: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 113    Japan: Key Macro & Micro Indicators 
    Table 114    Japan: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 115    Japan: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 116    Japan: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 117    Japan: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 118    Japan: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 119    India: Key Macro & Micro Indicators 
    Table 120    India: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 121    India: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 122    India: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 123    India: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 124    India: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 125    Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030 
    Table 126    Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 127    Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 128    Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 129    Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 130    Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 131    Latin America: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 132    Latin America: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 133    Latin America: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 134    Latin America: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 135    Latin America: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 136    Middle East & Africa: Cancer/Tumor Profiling Market, by Biomarker Type, 2022–2031 (USD Million) 
    Table 137    Middle East & Africa: Cancer/Tumor Profiling Market, by Technology, 2022–2031 (USD Million) 
    Table 138    Middle East & Africa: Cancer/Tumor Profiling Market, by Cancer Type, 2022–2031 (USD Million) 
    Table 139    Middle East & Africa: Cancer/Tumor Profiling Market, by Application, 2022–2031 (USD Million) 
    Table 140    Middle East & Africa: Cancer/Tumor Profiling Market, by End User, 2022–2031 (USD Million) 
    Table 141    Recent Developments, by Company, 2021-2024 

    List of Figures
    Figure 1    Research Process 
    Figure 2    Secondary Sources Referenced for This Study 
    Figure 3    Primary Research Techniques 
    Figure 4    Key Executives Interviewed 
    Figure 5    Breakdown of Primary Interviews (Supply-Side & Demand-Side) 
    Figure 6    Market Sizing and Growth Forecast Approach 
    Figure 7    Global Cancer/Tumor Profiling Market, by Biomarker Type, 2024 Vs. 2031 
    Figure 8    Global Cancer/Tumor Profiling Market, by Technology, 2024 Vs. 2031 (USD Million) 
    Figure 9    Global Cancer/Tumor Profiling Market, by Cancer Type, 2024 Vs. 2031
    Figure 10    Global Cancer/Tumor Profiling Market, by Application, 2024 Vs. 2031
    Figure 11    Global Cancer/Tumor Profiling Market, by End User, 2024 Vs. 2031
    Figure 12    Global Cancer/Tumor Profiling Market, by Geography
    Figure 13    Global Cancer/Tumor Profiling Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2024–2031) 
    Figure 14    Number of Cancer Cases, by Region, 2020 
    Figure 15    Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2020 (USD Million) 
    Figure 16    Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion) 
    Figure 17    Percentage of Approved Personalized Medicines, by Disease, 2022 
    Figure 18    Percentage of FDA Approvals for Personalized Medicines, 2015–2022 
    Figure 19    Percentage of Oncology Trials Incorporating Biomarkers, 2000–2019 
    Figure 20    Global Increase in The Number of Personalized Medicines, 2008–2020 
    Figure 21    USFDA Regulatory Pathways for IVD Kits 
    Figure 22    EU Regulatory Pathway - IVDR 2017/746 
    Figure 23    China: Medical Device Classification and Premarket Requirements for Cancer/Tumor Profiling Products 
    Figure 24    Porter's Five Forces Analysis 
    Figure 25    Global Cancer/Tumor Profiling Market, by Biomarker Type, 2024 Vs. 2031 (USD Million) 
    Figure 26    Global Cancer/Tumor Profiling Market, by Cancer Type 2024 Vs. 2031 (USD Million) 
    Figure 27    Global Cancer/Tumor Profiling Market, by Technology, 2024 Vs. 2031 (USD Million) 
    Figure 28    Global Cancer/Tumor Profiling Market, by Application, 2024 Vs. 2031 (USD Million) 
    Figure 29    FDA Approvals for Personalized Medicine (%) (2015–2021) 
    Figure 30    Global Cancer/Tumor Profiling Market, by End User, 2024 Vs. 2031 (USD Million) 
    Figure 31    Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion) 
    Figure 32    Global Cancer/Tumor Profiling Market, by Geography, 2024 Vs. 2031 (USD Million) 
    Figure 33    North America Cancer/Tumor Profiling Market Snapshot 
    Figure 34    U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion) 
    Figure 35    Europe: Pharmaceutical Industry R&D Expenditure (2000–2021) 
    Figure 36    Europe: Cancer/Tumor Profiling Market Snapshot 
    Figure 37    U.K: Number of Cancer Cases, 2010–2030 (In Million) 
    Figure 38    Italy: Ovarian Cancer Diagnoses (2018–2020) 
    Figure 39    Italy: Number of Biotechnology Firms, 2010-2021 
    Figure 40    Rest of Europe: Pharmaceutical R&D Expenditure, 2020 
    Figure 41    Asia-Pacific: Cancer/Tumor Profiling Market Snapshot 
    Figure 42    Japan: New Cancer Cases Reported (2020–2040) 
    Figure 43    Latin America: Estimated Number of New Cancer Cases (2020–2030) 
    Figure 44    Middle East & Africa: Number of New Cancer Cases, by Country/Region (2020) 
    Figure 45    Key Growth Strategies Adopted by Leading Players, 2021– 2024 
    Figure 46    Cancer/Tumor Profiling Market: Competitive Benchmarking by Offering 
    Figure 47    Cancer/Tumor Profiling Market: Competitive Benchmarking by Technology 
    Figure 48    Cancer/Tumor Profiling Market: Competitive Benchmarking, by Region 
    Figure 49    Global Cancer/Tumor Profiling Market Share Analysis, by Key Players, 2023 (%) 
    Figure 50    Competitive Dashboard: Cancer/Tumor Profiling Market 
    Figure 51    Thermo Fisher Scientific, Inc.: Financial Overview (2023) 
    Figure 52    Illumina, Inc.: Financial Overview (2023) 
    Figure 53    Qiagen N.V.: Financial Overview (2023) 
    Figure 54    F. Hoffmann-La Roche Ltd: Financial Overview (2023) 
    Figure 55    Exact Sciences Corporation: Financial Overview (2023) 
    Figure 56    Agilent Technologies, Inc.: Financial Overview (2023) 
    Figure 57    NanoString Technologies, Inc.: Financial Overview (2023) 
    Figure 58    HTG Molecular Diagnostics, Inc.: Financial Overview (2023) 
    Figure 59    Personalis, Inc.: Financial Overview (2023)

    Enquire
    Check Discount
    COVID-19

    This report provides pre & post COVID-19 market estimates.

    Download sample here
    Related Tag: Cancer/Tumor Profiling Market Molecular Profiling Cancer Molecular Profiling Comprehensive Genomic Profiling Cancer Gene Profiling Cancer Biomarkers Testing Solid Tumor Profiling
    Medical Technologies
    Healthcare
      This website is secure and we do not share your personal information with any third party. privacy policy
      COVID-19

      This report provides pre & post COVID-19 market estimates.

      Related Tag: Cancer/Tumor Profiling Market Molecular Profiling Cancer Molecular Profiling Comprehensive Genomic Profiling Cancer Gene Profiling Cancer Biomarkers Testing Solid Tumor Profiling
      Request Sample
      Customize My Report
      Linkdin
      Whatsapp
      Feed
      Related Reports
      Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)

         Published Date: Feb-2024

      Point of care Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2023-2030)

         Published Date: May-2023

      Tissue Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2022-2029)

         Published Date: Nov-2022

      North America Tissue Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)

         Published Date: Jun-2024

      Oncology Information Systems Market - Global Opportunity Analysis and Industry Forecast (2024-2030)

         Published Date: Jun-2024

      Table Of Content
      Download Free Sample Report
      Meticulous Research
      US
      +1 646-781-8004
      Meticulous Research
      Europe
      +44-203-868-8738
      Meticulous Research
      APAC
      +91-744-778-0008